Rationally Designed Enzyme‐Resistant Peptidic Assemblies for Plasma Membrane Targeting in Cancer Treatment
Source abstract
Abstract
Abstract Peptides are being increasingly important for subcellular targeted cancer treatment to improve specificity and reverse multidrug resistance. However, there has been yet any report on targeting plasma membrane (PM) through self‐assembling peptides. A simple synthetic peptidic molecule (tF4) is developed. It is revealed that tF4 is carboxyl esterase‐resistant and self‐assembles into vesical nanostructures. Importantly, tF4 assemblies interact with PM through orthogonal hydrogen bonding and hydrophobic interaction to regulate cancer cellular functions. Mechanistically, tF4 assemblies induce stress fiber formation, cytoskeleton reconstruction, and death receptor 4/5 (DR4/5) expression in cancer cells. DR4/5 triggers extrinsic caspase‐8 signaling cascade, resulting in cell death. The results provide a new strategy for developing enzyme‐resistant and PM‐targeting peptidic molecules against cancer.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Supramolecular Self-Assembly in Materials · Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
National Engineering Research Centre of Ophthalmology and Optometry School of Biomedical Engineering Eye Hospital Wenzhou Medical University Wenzhou 325027 China
Henan Eye Institute Henan Eye Hospital People's Hospital of Zhengzhou University Henan University School of Medicine Henan Provincial People's Hospital Zhengzhou Henan 450003 China
Key Laboratory of Biorheological Science and Technology Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
Wenzhou Institute University of Chinese Academy of Sciences 1 Jinlian Road Wenzhou 325000 China
Funding
National Natural Science Foundation of China · Wenzhou Medical University
References (50)
Show source-provided references
1. 10.3322/caac.2165410.3322/caac.21654 ↗
2. 10.1186/s12935-022-02624-910.1186/s12935-022-02624-9 ↗
3. 10.1002/anie.20211707510.1002/anie.202117075 ↗
4. 10.1002/anie.20220405210.1002/anie.202204052 ↗
5. 10.1007/978-1-4939-2272-7_310.1007/978-1-4939-2272-7_3 ↗
6. 10.1002/anie.20190088410.1002/anie.201900884 ↗
7. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
8. 10.1038/s41568-018-0005-810.1038/s41568-018-0005-8 ↗
9. 10.1021/jacs.7b1146210.1021/jacs.7b11462 ↗
10. 10.1186/s12951-021-01181-z10.1186/s12951-021-01181-z ↗
11. 10.1002/anie.20210734710.1002/anie.202107347 ↗
12. 10.1038/s41467-021-23793-710.1038/s41467-021-23793-7 ↗
13. 10.1016/j.cell.2020.02.00110.1016/j.cell.2020.02.001 ↗
14. 10.1002/adhm.20220202410.1002/adhm.202202024 ↗
15. 10.1002/adfm.20220092410.1002/adfm.202200924 ↗
16. 10.1002/anie.20140303610.1002/anie.201403036 ↗
17. 10.1002/adhm.20220144110.1002/adhm.202201441 ↗
18. 10.1002/adhm.20200123910.1002/adhm.202001239 ↗
19. 10.1039/C7CS90102J10.1039/C7CS90102J ↗
20. 10.1021/acsnano.0c0138810.1021/acsnano.0c01388 ↗
21. 10.1039/C7CS00735C10.1039/C7CS00735C ↗
22. 10.1016/j.biomaterials.2021.12113910.1016/j.biomaterials.2021.121139 ↗
23. 10.1039/D0CS00011F10.1039/D0CS00011F ↗
24. 10.1002/adhm.20200041610.1002/adhm.202000416 ↗
25. 10.1186/s12951-021-01076-z10.1186/s12951-021-01076-z ↗
26. 10.1038/s41421-020-00233-210.1038/s41421-020-00233-2 ↗
27. 10.1016/j.devcel.2016.09.01110.1016/j.devcel.2016.09.011 ↗
28. 10.1016/j.scib.2022.08.03010.1016/j.scib.2022.08.030 ↗
29. 10.1021/acsami.9b1349210.1021/acsami.9b13492 ↗
30. 10.1039/C8FD00009C10.1039/C8FD00009C ↗
31. 10.1021/ja312704e10.1021/ja312704e ↗
32. 10.1039/c1cc10633c10.1039/c1cc10633c ↗
33. 10.1038/ncomms1588010.1038/ncomms15880 ↗
34. 10.1002/advs.20210550610.1002/advs.202105506 ↗
35. 10.1016/j.addr.2012.09.01910.1016/j.addr.2012.09.019 ↗
36. 10.1021/acs.chemrev.9b0000810.1021/acs.chemrev.9b00008 ↗
37. 10.1021/acs.chemrev.5b0029910.1021/acs.chemrev.5b00299 ↗
38. 10.1021/acsbiomaterials.0c0172310.1021/acsbiomaterials.0c01723 ↗
39. 10.1016/j.jconrel.2019.12.01110.1016/j.jconrel.2019.12.011 ↗
40. 10.1016/j.chempr.2017.01.00210.1016/j.chempr.2017.01.002 ↗
41. 10.1039/C9CC03460A10.1039/C9CC03460A ↗
42. 10.1021/jp108034n10.1021/jp108034n ↗
43. 10.1021/acs.chemrev.9b0005510.1021/acs.chemrev.9b00055 ↗
44. S. K.Bhal Advanced Chemistry Development Inc. Toronto ON Canada 2007.
45. 10.1083/jcb.20040312710.1083/jcb.200403127 ↗
46. 10.1083/jcb.20051109310.1083/jcb.200511093 ↗
47. 10.1016/j.molcel.2014.04.02910.1016/j.molcel.2014.04.029 ↗
48. 10.1016/j.cytogfr.2008.04.00110.1016/j.cytogfr.2008.04.001 ↗
49. 10.1089/ten.2006.038110.1089/ten.2006.0381 ↗
50. 10.7554/eLife.7302010.7554/eLife.73020 ↗